Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
As-needed versus regular use of MP-AzeFlu in moderate-to-severe allergic rhinitis
TCTR20230729001Phase 3Completed
- Sponsor
- Department of Otolaryngology
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of azelastine + fluticasone in allergic rhinitis (AR) (2 arms), sponsored by Department of Otolaryngology. Started Oct 2023; status: completed.
02
Drugs
azelastine + fluticasone
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on TCTR20230729001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230729001.